Table 2.

Frequency of treatment-emergent adverse events (AEs)

All treated patients (N = 20)
Treatment-emergent adverse events	Frequency (%)
Gastroenteritis	5 (25%)
Vomiting	2 (10%)
Upper respiratory tract infection	2 (10%)
Mouth ulceration	1 (5%)
Paraesthesia oral	1 (5%)
Diarrhea	1 (5%)
Application site dryness	1 (5%)
Application site rash	1 (5%)
Influenza	1 (5%)
Viral infection	1 (5%)
Viral upper respiratory tract infection	1 (5%)
Otitis media	1 (5%)
Tonsillitis	1 (5%)
Limb injury	1 (5%)
Eosinophil count abnormal	1 (5%)
Neck pain	1 (5%)
Pain in extremity	1 (5%)
Dizziness	1 (5%)
Lethargy	1 (5%)
Psychomotor hyperactivity	1 (5%)
Enuresis	1 (5%)
Stereotypy	1 (5%)
Nightmare	1 (5%)
Pruritus	1 (5%)
Eczema	1 (5%)
Rash pruritic	1 (5%)

Note. Frequency reflects all reported events; individual patients may have experienced more than one AE